Search by Drug Name or NDC
NDC 24208-0911-12 Xiidra 50 mg/mL Details
Xiidra 50 mg/mL
Xiidra is a OPHTHALMIC SOLUTION/ DROPS in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Bausch & Lomb Incorporated. The primary component is LIFITEGRAST.
MedlinePlus Drug Summary
Ophthalmic lifitegrast is used to treat the signs and symptoms of dry eye disease. Lifitegrast is in a class of medications called lymphocyte function-associated antigen-1 (LFA-1) antagonist. Lifitegrast works by reducing the swelling in the eye tissues.
Related Packages: 24208-0911-12Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Lifitegrast Ophthalmic
Product Information
| NDC | 24208-0911 |
|---|---|
| Product ID | 24208-911_0df822d2-3f12-e65c-e063-6394a90a3a39 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | Xiidra |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Lifitegrast |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SOLUTION/ DROPS |
| Route | OPHTHALMIC |
| Active Ingredient Strength | 50 |
| Active Ingredient Units | mg/mL |
| Substance Name | LIFITEGRAST |
| Labeler Name | Bausch & Lomb Incorporated |
| Pharmaceutical Class | Lymphocyte Function-Associated Antigen-1 Antagonist [EPC], Lymphocyte Function-Associated Antigen-1 Antagonists [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA208073 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 24208-0911-12 (24208091112)
| NDC Package Code | 24208-911-12 |
|---|---|
| Billing NDC | 24208091112 |
| Package | 12 POUCH in 1 CARTON (24208-911-12) / 5 AMPULE in 1 POUCH (24208-911-05) / .2 mL in 1 AMPULE |
| Marketing Start Date | 2024-01-02 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |